哺乳动物细胞表达的重组三聚体刺突蛋白是强效疫苗抗原,在仓鼠中可提供针对SARS-CoV-2感染的近乎完全保护
研究构建了重组预融合稳定三聚体刺突蛋白抗原IMT-CVAX,由IMT-C20基因编码并在CHO-S悬浮哺乳动物细胞系中表达。在小型动物中评估免疫原性,并在仓鼠攻毒模型中评估保护效力,结果显示佐剂化IMT-CVAX在小鼠和仓鼠中均诱导优异免疫应答,免疫血清可中和多种SARS-CoV-2变异株,免疫仓鼠获得完全保护。
要点
- IMT-CVAX为CHO-S细胞表达的预融合稳定三聚体刺突蛋白抗原。
- 佐剂化IMT-CVAX在小鼠和仓鼠中诱导优异免疫应答。
- 免疫血清可中和多种SARS-CoV-2变异株,仓鼠攻毒获完全保护。
核心结论
- 基于临床前模型评估,佐剂化IMT-CVAX是高度有效的疫苗候选,作为蛋白亚单位疫苗有望用于临床开发,为SARS-CoV-2变异株的原发和异源免疫提供可负担的方案。
研究设计与样本
- 研究将IMT-C20基因整合入CHO基因组建立稳定表达IMT-CVAX的CHO-S细胞系,经表达、纯化和表征后在小动物中评估免疫原性,并用仓鼠攻毒模型评估保护效力。
主要发现
- 佐剂化IMT-CVAX在小鼠和仓鼠中均诱导优异免疫应答。
- IMT-CVAX免疫动物的血清可有效中和多种SARS-CoV-2变异株。
- IMT-CVAX免疫使仓鼠对SARS-CoV-2感染获得完全保护。
- 在hACE2转基因小鼠中,IMT-CVAX接种诱导强烈的GC-B和Tfh细胞应答。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Numerous vaccine candidates have emerged in the fight against SARS-CoV-2, yet the challenges posed by viral evolution and the evasion of vaccine-induced immunity persist. The development of broadly protective vaccines is essential in countering the threat posed by variants of concern (VoC) capable of eluding existing vaccine defenses. Among the diverse SARS-CoV-2 vaccine candidates, detailed characterization of those based on the expression of the entire spike protein in mammalian cells have been limited. In our study, we engineered a recombinant prefusion-stabilized trimeric spike protein antigen, IMT-CVAX, encoded by the IMT-C20 gene. This antigen was expressed utilizing a suspension mammalian cell line (CHO-S). The establishment of a stable cell line expressing IMT-CVAX involved the integration of the gene into the CHO genome, followed by the expression, purification, and characterization of the protein. To gauge the vaccine potential of adjuvanted IMT-CVAX, we conducted assessments in small animals. Analyses of blood collected from immunized animals included measurements of anti-spike IgG, SARS-CoV-2 neutralization, and responses from GC-B and Tfh cells. Furthermore, the protective efficacy of IMT-CVAX was evaluated using a Hamster challenge model. Our findings indicate that adjuvanted IMT-CVAX elicits an excellent immune response in both mice and hamsters. Notably, sera from animals immunized with IMT-CVAX effectively neutralize a diverse range of SARS-CoV-2 variants. Moreover, IMT-CVAX immunization conferred complete protection to hamsters against SARS-CoV-2 infection. In hACE2 transgenic mice, IMT-CVAX vaccination induced a robust response from GC-B and Tfh cells. Based on our preclinical model assessments, adjuvanted IMT-CVAX emerges as a highly efficacious vaccine candidate. This protein-subunit-based vaccine exhibits promise for clinical development, offering an affordable solution for both primary and heterologous immunization against SARS-CoV-2 variants.
引用
- Jitender, Vikram Kumar B, Singh S, et al. Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster. Vaccine. 2024. PMID: 38981743. doi:10.1016/j.vaccine.2024.06.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。